Bio-Techne Corp (TECH) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Bio-Techne Corp stock (TECH) is currently trading at $52.69. Bio-Techne Corp PE ratio is 98.92. Bio-Techne Corp PS ratio (Price-to-Sales) is 6.75. Analyst consensus price target for TECH is $75.25. WallStSmart rates TECH as Underperform.
- TECH PE ratio analysis and historical PE chart
- TECH PS ratio (Price-to-Sales) history and trend
- TECH intrinsic value — DCF, Graham Number, EPV models
- TECH stock price prediction 2025 2026 2027 2028 2029 2030
- TECH fair value vs current price
- TECH insider transactions and insider buying
- Is TECH undervalued or overvalued?
- Bio-Techne Corp financial analysis — revenue, earnings, cash flow
- TECH Piotroski F-Score and Altman Z-Score
- TECH analyst price target and Smart Rating
Bio-Techne Corp
📊 No data available
Try selecting a different time range
TECH Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Bio-Techne Corp (TECH)
TECH trades 461% above its Graham fair value of $11.32, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Bio-Techne Corp (TECH) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, institutional own.. Concerns around return on equity and revenue growth. Mixed signals suggest waiting for clearer direction before acting.
Bio-Techne Corp (TECH) Key Strengths (3)
Growing significantly faster than its price suggests
113.90% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Bio-Techne Corp (TECH) Areas to Watch (7)
Revenue declining -0.40%, a shrinking business
Very low returns on shareholder equity
Premium valuation at 6.8x annual revenue
Premium pricing at 4.0x book value
Modest earnings growth at 9.10%
Thin profit margins with limited profitability
Decent operational efficiency, solid but not exceptional
Supporting Valuation Data
Bio-Techne Corp (TECH) Detailed Analysis Report
Overall Assessment
This company scores 48/100 in our Smart Analysis, earning a D+ grade. Out of 10 metrics analyzed, 3 register as strengths (avg 9.0/10) while 7 fall into concern territory (avg 3.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Institutional Own., Market Cap. Valuation metrics including PEG Ratio (0.66) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Revenue Growth, Return on Equity, Price/Sales. Some valuation metrics including Price/Sales (6.75), Price/Book (4.01) suggest expensive pricing. Growth concerns include Revenue Growth at -0.40%, EPS Growth at 9.10%, which may limit upside. Profitability pressure is visible in Return on Equity at 3.97%, Operating Margin at 19.70%, Profit Margin at 6.67%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Revenue Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 3.97% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -0.40% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Revenue Growth and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
TECH Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
TECH's Price-to-Sales ratio of 6.75x trades at a deep discount to its historical average of 35.1x (2th percentile). The current valuation is 86% below its historical high of 49.6x set in Jun 2008, and 7% above its historical low of 6.28x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~7.6x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Bio-Techne Corp (TECH) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Bio-Techne Corp operates as a stable business with moderate growth and solid fundamentals. Revenue reached 1.2B with 0% growth year-over-year. Profit margins are thin at 6.7%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
Generating 76M in free cash flow and 82M in operating cash flow. Earnings are translating into actual cash generation.
ROE of 4.0% suggests the company isn't efficiently converting equity into profits.
What to Watch Next
Margin expansion: can Bio-Techne Corp push profit margins above 15% as the business scales?
Valuation compression risk at a P/E of 98.9x. Any growth miss could trigger a sharp correction.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Bio-Techne Corp.
Bottom Line
Bio-Techne Corp offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(10 last 3 months)
| Insider | Type | Shares |
|---|---|---|
HERR, AMY E. Director | Sell | -1,976 |
Data sourced from SEC Form 4 filings
Last updated: 10:02:17 AM
About Bio-Techne Corp(TECH)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and services for the global clinical diagnostic and research markets. The company is headquartered in Minneapolis, Minnesota.